Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Blvd., Suite 105, Scottsdale, United States

MightyPumperDuck May. 15 at 11:39 AM

$DERM Because of subsequent ER's, the ticker has reflected reality. IMO, we have a gap to fill at around $5.50 and then another run up in July/August. I see no reason for the narrative to change with SP action. IMO, it comes back to $5.50 before running to $7. I'm more than happy with that.

0 · Reply

topstockalerts May. 14 at 8:33 PM

$DERM the trend is building without much fanfare.

0 · Reply

buymoremakemore May. 14 at 3:42 PM

$DERM i want 5k more. Will look for any dip.

0 · Reply

alecsalaur198 May. 14 at 3:23 PM

$DERM 10 $ soon

1 · Reply

FinSUN May. 14 at 3:00 PM

$DERM

0 · Reply

alecsalaur198 May. 14 at 2:54 PM

$DERM a low volume stock with stronger fundamentals is a ticking bomb with more than 3 mil in short

0 · Reply

STACKD0E May. 14 at 2:28 PM

$DERM

0 · Reply

alecsalaur198 May. 14 at 2:06 PM

$DERM over 3 mil.shares short with this low volume can be very bad for shorts

0 · Reply

makrodimutross May. 14 at 2:03 PM

$DERM $FBIO $FBIOP The jury is in. On the heels of excellent growth indicators for EMROSI, The market remains relentless with its punishment of FBIO for their neglect of the preferred stockholders. If 100m cash isnt enough to reinstate dividends, what IS enough? BOD better provide Q1 guidance, or i see a 1.xx handle for FBIO in the near future.

2 · Reply

gb11 May. 14 at 1:58 PM

$DERM Selling at 6 doesn't make sense right now. Shorts got too greedy and overextended, over 25% short interest. They just have two options, cover now or get burned later. I can hold for one or two quarters knowing that my derm thesis is correct.

0 · Reply

Journey Medical reports Q1 EPS 2c vs. (4c) last year

May 13, 2026, 4:30 PM EDT - 1 day ago

Journey Medical Earnings Call Transcript: Q1 2026

May 13, 2026, 4:01 PM EDT - 1 day ago

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

FBIO

May 6, 2026, 4:01 PM EDT - 8 days ago

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

FBIO

2026-04-21T13:01:14.000Z - 23 days ago

Journey Medical secures contract with third major GPO for Emrosi

Apr 21, 2026, 8:30 AM EDT - 24 days ago

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

FBIO

Apr 2, 2026, 1:03 PM EDT - 6 weeks ago

Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-26T12:51:06.000Z - 7 weeks ago

Journey Medical price target raised to $12 from $11 at B. Riley

2026-03-25T22:20:17.000Z - 7 weeks ago

Journey Medical reports FY25 EPS (47c) vs. (72c) last year

Mar 25, 2026, 4:30 PM EDT - 7 weeks ago

Journey Medical Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:01 PM EDT - 7 weeks ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

FBIO

Mar 18, 2026, 8:30 AM EDT - 2 months ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

FBIO

2026-02-18T16:15:21.000Z - 3 months ago

Journey Medical management to meet virtually with Lake Street

2026-01-15T21:50:14.000Z - 4 months ago

Journey Medical files $150M mixed securities shelf

2025-12-10T13:50:12.000Z - 5 months ago

Journey Medical announces results from Phase 1 trial of DFD-29

Dec 10, 2025, 8:30 AM EST - 5 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

FBIO

2025-11-13T12:11:48.000Z - 6 months ago

Journey Medical price target raised to $16 from $10 at Alliance Global

Nov 12, 2025, 4:30 PM EST - 6 months ago

Journey Medical Earnings Call Transcript: Q3 2025

2025-11-12T21:12:01.000Z - 6 months ago

Journey Medical reports Q3 EPS (9c), consensus (4c)

Nov 12, 2025, 4:01 PM EST - 6 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

2025-11-12T13:30:21.000Z - 6 months ago

Fourteen new option listings on November 12th

BBNX IMDX MST PRE

Nov 5, 2025, 8:30 AM EST - 6 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

FBIO

2025-10-24T12:36:06.000Z - 7 months ago

Journey Medical presented efficacy data from two studies on Emrosi

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FBIO

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

FBIO

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

FBIO

2025-08-25T10:05:18.000Z - 9 months ago

Journey Medical initiated with a Buy at H.C. Wainwright

Aug 20, 2025, 12:35 PM EDT - 9 months ago

Journey Medical Transcript: Emerging Growth Conference 85

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

FBIO

2025-08-13T13:11:17.000Z - 9 months ago

Journey Medical price target raised to $13 from $9 at Lake Street

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Journey Medical Earnings Call Transcript: Q2 2025

2025-08-12T20:21:30.000Z - 9 months ago

Journey Medical reports Q2 EPS (16c) vs. (17c) last year

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

FBIO

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

FBIO

2025-07-30T12:36:09.000Z - 10 months ago

Journey Medical price target raised to $12 from $9 at B. Riley

2025-07-14T12:41:42.000Z - 10 months ago

Journey Medical announces expanded payer coverage for Emrosi

Jul 14, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

FBIO

2025-06-24T12:45:37.000Z - 11 months ago

Journey Medical to join Russell 2000, Russell 3000 Indexes

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

FBIO

Jun 20, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

FBIO

Jun 9, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

FBIO

May 14, 2025, 4:30 PM EDT - 1 year ago

Journey Medical Earnings Call Transcript: Q1 2025

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

FBIO

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

FBIO

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Journey Medical Earnings Call Transcript: Q4 2024

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

FBIO

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

FBIO

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

FBIO

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

FBIO

Mar 5, 2025, 4:01 PM EST - 1 year ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

FBIO

Mar 4, 2025, 4:01 PM EST - 1 year ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

FBIO

Feb 5, 2025, 4:30 PM EST - 1 year ago

Journey Medical Transcript: Status Update

Jan 23, 2025, 8:30 AM EST - 1 year ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Nov 12, 2024, 4:01 PM EST - 1 year ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Nov 4, 2024, 8:30 AM EST - 1 year ago

Journey Medical Transcript: FDA Announcement

Nov 4, 2024, 7:00 AM EST - 1 year ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

FBIO

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

FBIO

Sep 4, 2024, 8:15 AM EDT - 1 year ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Journey Medical Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

FBIO

Jul 11, 2024, 4:05 PM EDT - 2 years ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

FBIO

May 15, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

FBIO

May 13, 2024, 4:30 PM EDT - 2 years ago

Journey Medical Earnings Call Transcript: Q1 2024

May 13, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

FBIO

May 1, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

FBIO

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

FBIO

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Journey Medical Earnings Call Transcript: Q4 2023

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

FBIO

Mar 18, 2024, 12:30 PM EDT - 2 years ago

Journey Medical Transcript: Roth MKM 36th Annual ROTH Conference

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

FBIO

Mar 15, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

FBIO

Mar 13, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

FBIO

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

FBIO

MightyPumperDuck May. 15 at 11:39 AM

0 · Reply

topstockalerts May. 14 at 8:33 PM

$DERM the trend is building without much fanfare.

0 · Reply

buymoremakemore May. 14 at 3:42 PM

$DERM i want 5k more. Will look for any dip.

0 · Reply

alecsalaur198 May. 14 at 3:23 PM

$DERM 10 $ soon

1 · Reply

FinSUN May. 14 at 3:00 PM

$DERM

0 · Reply

alecsalaur198 May. 14 at 2:54 PM

$DERM a low volume stock with stronger fundamentals is a ticking bomb with more than 3 mil in short

0 · Reply

STACKD0E May. 14 at 2:28 PM

$DERM

0 · Reply

alecsalaur198 May. 14 at 2:06 PM

$DERM over 3 mil.shares short with this low volume can be very bad for shorts

0 · Reply

makrodimutross May. 14 at 2:03 PM

2 · Reply

gb11 May. 14 at 1:58 PM

0 · Reply

ExtraRun123 May. 14 at 1:53 PM

$DERM Stay patient. No reason to sell at $6. Look at the chart, the stock traded above $7.50 for most of the year, and the story has only improved since then: Demand is there. Coverage is improving. April was already very strong. Let the shorts figure out how to get out!

2 · Reply

alecsalaur198 May. 14 at 1:52 PM

$DERM this will be over 10 in next 6 months

1 · Reply

gb11 May. 14 at 1:49 PM

$DERM I was always bullish about this stock since I did a comprehensive DD for last two months but was frustrated with shit price action by shorts trying to keep the price down, but I knew it just needed a catalyst to continue the upward momentum. The continued growth of emrosi is proving to be that catalyst. Shorts has until the end of this quarter to cover or they will be burned in the upcoming quarters.

0 · Reply

alecsalaur198 May. 14 at 1:47 PM

$DERM bought here

0 · Reply

FinSUN May. 14 at 1:45 PM

$DERM new bagholders machine

1 · Reply

buymoremakemore May. 14 at 1:44 PM

$DERM Was surprised by premarket. This opening rules!!

0 · Reply

gb11 May. 14 at 1:41 PM

$DERM would be looking to sell 10$+ in the coming quarters. Stock price will easily will reach 20$ by 2027.

0 · Reply

JFais May. 14 at 1:39 PM

$DERM (L) -Operating leverage will continue to increase throughout 2026 -Ratio of refills to new prescriptions now approaching 1.5 to 1 (up from 1 to 1 at end of 2025). Expected to increase going forward -ASP for Emrosi will continue to strengthen as they rely less on their copay bridging program -Formulary coverage to broaden this year and next (single step edit through any oral or topical agent with a lookback of 1 year or greater)

0 · Reply

ExtraRun123 May. 14 at 1:35 PM

$DERM should rebound to at least $7.50 over the coming days. Hard to believe many holders would be willing to sell at $6.

0 · Reply

JFais May. 14 at 1:34 PM

$DERM (L) Double down post Q4 gap-down working out well

0 · Reply

ExtraRun123 May. 14 at 11:18 AM

$DERM I don’t see how shorts get out of this without pushing the stock much higher

0 · Reply

DonCorleone77 May. 14 at 3:04 AM

$CSCO $GO $STAA $STUB $DERM AFTER-HOURS MOVERS: Currently Higher After Earnings: - Cisco (CSCO) up 19.8% - Grocery Outlet (GO) up 16.4% - STAAR Surgical (STAA) up 14.4% - StubHub Holdings (STUB) up 12.6% - Journey Medical (DERM) up 7.1% - Jack in the Box (JACK) up 2.2% Currently Also Higher: - SharkNinja (SN) up 5.7% after entering S&P MidCap 400 index - F&G Annuities & Life (FG) up 4.0% after entering S&P SmallCap 600 index Currently Lower After Earnings: - Doximity (DOCS) down 18.2% - Enovix (ENVX) down 12.4% Currently Also Lower: - PDF Solutions (PDFS) down 9.9% after equity offering - Kodiak Gas Services (KGS) down 5.5% after equity offering

0 · Reply

Market Cap	141.85M
Revenue (ttm)	61.86M
Net Income (ttm)	-11.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	26.37
Profit Margin	-18.48%
Debt to Equity Ratio	0.79

Volume	763,700
Avg Vol	269,760
Day's Range	N/A - N/A
Shares Out	27.33M
Stochastic %K	81%
Beta	1.03
Analysts	Strong Sell
Price Target	$13.25